Dharmacon and amaxa collaborate to improve siRNA delivery into cells

08-Jun-2006

Dharmacon, Inc., a business unit of the Fisher Biosciences group, and amaxa announced an agreement to co-promote data generated using Dharmacon's siRNA libraries with amaxa's Nucleofector® technology.

Despite the rapid advance of RNAi gene silencing for drug discovery and development, some research has been hampered by the insufficient delivery of siRNA into primary cells and non-standard cell lines. Nucleofection gives researchers the ability to efficiently transfer nucleic acids (siRNA) into those cells and use them for gene silencing experiments. amaxa's new Nucleofector® 96-well Shuttle(TM) system allows parallel processing of a large number of transfection experiments and works well with Dharmacon's libraries as well as smaller siRNA samples.

"The combined technologies of Dharmacon and amaxa enable us to broaden the application of siRNA so that it can be introduced into difficult cell lines, and with the 96-well Shuttle system researchers can also accomplish this in high throughput," said William S. Marshall, Ph.D., vice president of technology and business development for Fisher Biosciences. "We will work closely with amaxa to provide our customers with coordinated technical service, pre-tested protocols and application models to optimize the use of our siRNA reagents with the amaxa technology."

https://www.bionity.com/en/news/55360/dharmacon-and-amaxa-collaborate-to-improve-sirna-delivery-into-cells.html